Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China.
J BUON. 2021 May-Jun;26(3):1002-1008.
The purpose of this study was to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with capecitabine and cetuximab in the treatment of colorectal cancer with liver metastasis.
The colorectal cancer patients with liver metastasis were divided into two groups, namely, Capecitabine group (receiving TACE combined with capecitabine and cetuximab, n=70) and Control group (undergoing TACE combined with cetuximab, n=70). The short-term clinical efficacy, serum tumor markers and liver function indexes were compared. Besides, the survival of patients was analyzed.
At 3 months after treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and vascular endothelial growth factor (VEGF) were significantly lower than those before treatment in both group, and they were lower in Capecitabine group than those in Control group after treatment. The liver function indexes, alanine aminotransferase and aspartate aminotransferase, were significantly increased, while the level of albumin was significantly decreased in both groups at 3 d after treatment, and they were improved significantly at 7 d after treatment in contrast with those at 3 d after treatment. After treatment, there were no statistically significant differences in the Karnofsky performance status score and Quality of Life score between Capecitabine group and Control group. The median survival time of patients in Capecitabine group and Control group was 18.1 months and 14.7 months, respectively. There was a statistically significant difference in the 1-year overall survival rate between Capecitabine group and Control group. Moreover, the cumulative survival rate was significantly higher in Capecitabine group than that in Control group.
The short-term efficacy of TACE combined with capecitabine and cetuximab in treating colorectal cancer with liver metastasis is superior to that of TACE combined with cetuximab.
本研究旨在探讨经导管动脉化疗栓塞（TACE）联合卡培他滨和西妥昔单抗治疗结直肠癌肝转移的疗效和安全性。
将结直肠癌肝转移患者分为两组，卡培他滨组（接受 TACE 联合卡培他滨和西妥昔单抗治疗，n=70）和对照组（接受 TACE 联合西妥昔单抗治疗，n=70）。比较两组患者的近期临床疗效、血清肿瘤标志物和肝功能指标，并分析患者的生存情况。
治疗 3 个月后，两组患者的血清癌胚抗原（CEA）、糖类抗原 19-9（CA19-9）和血管内皮生长因子（VEGF）水平均明显低于治疗前，且卡培他滨组治疗后明显低于对照组；两组患者治疗后 3 d 时的肝功能指标丙氨酸氨基转移酶和天冬氨酸氨基转移酶明显升高，白蛋白水平明显降低，治疗后 7 d 时明显改善，与治疗后 3 d 时相比，差异均有统计学意义。治疗后，卡培他滨组和对照组患者的卡氏功能状态评分和生活质量评分差异均无统计学意义。卡培他滨组和对照组患者的中位生存时间分别为 18.1 个月和 14.7 个月，卡培他滨组患者的 1 年总生存率明显高于对照组，差异有统计学意义。此外，卡培他滨组患者的累积生存率明显高于对照组。
TACE 联合卡培他滨和西妥昔单抗治疗结直肠癌肝转移的近期疗效优于 TACE 联合西妥昔单抗。
